Finally, nine studies that were published between 2000 and 2013 were eligible for our meta-analysis that aimed to elucidate the impact of CXCR4 as a prognostic and clinicopathological biomarker in pancreatic cancer [6, 16, 17, 36–41]. The gene discussed is CXCR4; the disease is familial pancreatic carcinoma.